High Blood Pressure Care for Korean Americans
The primary objective of the proposed clinical trials is to compare the differential reduction in blood pressure in underserved hypertensive adult Korean American. The study is designed to test the effectiveness of a comprehensive self-help intervention program.
Description
CVD is the leading cause of mortality among KA. Recent statistics underscoring the high prevalence and impact of uncontrolled HBP upon this population warrant the development and implementation of effective intervention. KA experiences a great deal of social isolation, which makes it more difficult for them to make behavioral changes for health improvement. individual, family, and community behaviors are part of the HBP problem and also constitute major part of the solution. The proposed research is designed to investigate these issues in a KA population and to lay the groundwork for community-based self-help health education interventions to enhance appropriate care and BP control.
Comparison(s):This community-based self-help intervention approach offers a more culturally appropriate approach to closing the health status gap for KA. Incorporating a partnership with community leaders and health and human service care providers, this approach will utilize state-of-the-art health education strategies and a well-trained bilingual nurse from the community.
Status: Completed (N/A). Started on September 1st, 2003. Ended on August 1st, 2007.
Enrollment: 445 subjects
Study Type: Interventional
Study Design:
- Treatment
- Randomized
- Single Blind
- Active Control
- Parallel Assignment
- Efficacy Study
Conditions:
Interventions:
- Behavioral: Self-Help Intervention Program-High Blood Pressure
Eligibility
Inclusion Criteria:
Self-identified as first-generation Korean American
Age 40 to 65 years of age
SBP≥140 or DBP≥90mmHg on HBP medication
resident of Greater Baltimore census tracts
Written consent to participate in the screening/eligibility visit
SBP≥140 or DBP≥90mmHg at the KRC HBP verification visit
Written consent to participate in the clinical trial:agreeing to participate in study data collection procedures, receiving HBP education, using HBPMT, and permitting contact with their own medical care provider.
Exclusion Criteria:
Acute and/or terminal condition precluding participation such as terminal cancer or acute myocardial infarction
Psychiatric diagnosis precluding participation such as schizophrenia and cognitive impairment measured by self-report, chart review, or clinical assessment.
- Gender
Both
- Mininum Age
40 Years
- Maximum Age
65 Years
- Healthy Volunteers
No
Resources
Source: Johns Hopkins University
Authority: United States: Institutional Review Board
Locations
-
Korean Resource Center
Ellicott city
Maryland
21042
United States
Officials
Miyong D Kim, PhD (Principal Investigator, Johns Hopkins university, School of Nursing)
Sponsors
Johns Hopkins University (Lead Sponsor)
Agency for Healthcare Research and Quality (AHRQ) (Collaborator)
References
Han HR, Kang J, Kim KB, Ryu JP, Kim MT. Barriers to and strategies for recruiting Korean Americans for community-partnered health promotion research. J Immigr Minor Health. 2007 Apr;9(2):137-46.
PMID: 17186370.
Check for Full Text
Links
None.
- Date Verified
- May 1st, 2008
- First Received
- May 5th, 2008
- Last Changed
- May 5th, 2008
Information obtained from ClinicalTrials.gov on July 15, 2008. Link to the current ClinicalTrials.gov record.
All data in the Healia Clinical Trials Information Database and content displayed by the Healia Clinical Trials Search Engine are licensed from the National Institutes of Health (National Library of Medicine), which collects and maintains the data.
The Healia Clinical Trials Search Engine searches the data set at clinicaltrials.gov, providing up-to-date information about current clinical trials. In the Healia Clinical Trials Database you can find information on new experimental drugs, medical devices, and other types of treatments for all types of diseases. Each clinical trial description includes information about the phase of the trial (phase I, phase II, or phase III), the trial’s methods, such as whether it is a randomized, placebo controlled, double blind study, and the status of the trial including whether or not the trial is currently enrolling new participants.
